Lantheus (NASDAQ:LNTH) Receives “Buy” Rating from Truist Financial

Truist Financial restated their buy rating on shares of Lantheus (NASDAQ:LNTH) in a report issued on Friday, Benzinga reports. Truist Financial currently has a $125.00 price objective on the medical equipment provider’s stock.

Other equities analysts have also issued reports about the stock. TheStreet raised shares of Lantheus from a c rating to a b- rating in a report on Wednesday, August 9th. StockNews.com began coverage on shares of Lantheus in a research note on Thursday, August 17th. They issued a buy rating on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus has an average rating of Buy and a consensus price target of $121.83.

Lantheus Price Performance

NASDAQ:LNTH opened at $64.10 on Friday. Lantheus has a 52 week low of $47.46 and a 52 week high of $100.85. The firm has a market cap of $4.39 billion, a price-to-earnings ratio of 156.34 and a beta of 0.68. The firm’s 50-day simple moving average is $73.57 and its 200 day simple moving average is $81.84. The company has a debt-to-equity ratio of 1.01, a quick ratio of 4.55 and a current ratio of 4.88.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 3rd. The medical equipment provider reported $1.40 EPS for the quarter, beating the consensus estimate of $1.23 by $0.17. Lantheus had a net margin of 2.97% and a return on equity of 67.18%. The firm had revenue of $321.70 million for the quarter, compared to analyst estimates of $306.48 million. As a group, sell-side analysts predict that Lantheus will post 5.19 earnings per share for the current year.

Insider Buying and Selling

In related news, President Paul Blanchfield sold 408 shares of Lantheus stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $66.10, for a total transaction of $26,968.80. Following the sale, the president now directly owns 90,067 shares in the company, valued at approximately $5,953,428.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, President Paul Blanchfield sold 408 shares of Lantheus stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $66.10, for a total transaction of $26,968.80. Following the sale, the president now directly owns 90,067 shares in the company, valued at approximately $5,953,428.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Daniel Niedzwiecki sold 4,297 shares of Lantheus stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $67.93, for a total transaction of $291,895.21. Following the sale, the insider now owns 66,295 shares in the company, valued at $4,503,419.35. The disclosure for this sale can be found here. Insiders have sold a total of 19,315 shares of company stock worth $1,353,773 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several hedge funds have recently added to or reduced their stakes in the business. Altshuler Shaham Ltd bought a new position in Lantheus during the 2nd quarter worth approximately $27,000. Covestor Ltd raised its holdings in Lantheus by 102.5% during the 2nd quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 164 shares during the last quarter. SJS Investment Consulting Inc. raised its holdings in Lantheus by 6,460.0% during the 2nd quarter. SJS Investment Consulting Inc. now owns 328 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 323 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in Lantheus by 60.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 160 shares during the last quarter. Finally, National Bank of Canada FI raised its holdings in Lantheus by 35.7% during the 1st quarter. National Bank of Canada FI now owns 445 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 117 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.